Trametinib (DMSO solvate)
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate) ) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2]. This product is in solid form, a DMSO solvate, and a stable crystalline form.
Product Specifications
CAS Number
[1187431-43-1]
Product Name Alternative
GSK-1120212 (DMSO solvate) ; JTP-74057 (DMSO solvate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; MEK
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Trametinib-DMSO-solvate.html
Purity
99.56
Solubility
DMSO : 3.33 mg/mL (ultrasonic)
Smiles
CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
Molecular Formula
C28H29FIN5O5S
Molecular Weight
693.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61 (5), 445-454.|[2]Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate) . ACS Med Chem Lett. 2011 Feb 28;2 (4) :320-4.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
MEK1; MEK2
Citation 01
Cancer Cell. 2020 Mar 16;37 (3) :387-402.e7. |Cell Rep. 2021 Jul 20;36 (3) :109410.|Cell Rep. 2023 Dec 18;42 (12) :113586.|Faculty of Biology, University of Barcelona. 2020 Jan.|FASEB J. 2025 Aug 31;39 (16) :e70901.|Mol Cell. 2019 Jan 3;73 (1) :7-21.e7. |Patent. US20200046706A1.|Patent. US20210401844A1.|Patent. US20220162299A1.|Patent. US20220177583A1.|Physiol Behav. 2025 Aug 7:301:115059.|PLoS One. 2020 Sep 3;15 (9) :e0235824.|Sci Signal. 2018 Oct 30;11 (554) :eaar6795.|University of Leicester. 2023 Sep.|ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1475-1486.|Adv Healthc Mater. 2024 Dec;13 (32) :e2402685.|Adv Sci (Weinh) . 2023 Apr;10 (12) :e2201164.|Adv Sci (Weinh) . 2025 Aug 22:e08451.|Adv Sci (Weinh) . 2025 Jun 25:e15176.|Am J Dig Dis (Madison) . 2015;2 (2) :95-99.|Am J Respir Cell Mol Biol. 2019 Sep;61 (3) :355-366.|Anal Chem. 2024 Mar 19;96 (11) :4455-4462.|Angiogenesis. 2024 Nov;27 (4) :739-752.|Anticancer Res. 2025 Jun;45 (6) :2285-2295.|Aquaculture. 2023 Sep 23, 740148.|Aquaculture. 2024 Oct 15.|Arch Dermatol Res. 2025 Mar 1;317 (1) :514.|Biochem Biophys Rep. 2025 Jul 17:43:102164.|Biochem Biophys Rep. 2025 Sep 3:44:102235.|Biochem Biophys Res Commun. 2017 Aug 5;489 (4) :484-489.|Biochem Biophys Res Commun. 2018 Jan 8;495 (2) :1846-1850. |Biochem Biophys Res Commun. 2025 May 15:771:152027.|Biochem Pharmacol. 2025 Feb 7:116796.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomaterials. 2018 Sep;178:158-169.|Biomaterials. 2022 Oct:289:121800.|Biomolecules. 2021 Mar 30;11 (4) :518.|Biomolecules. 2023 Apr 25;13 (5) :740.|Biomolecules. 2025 Sep 30;15 (10) :1396.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Oct 23:2023.10.20.563266.|bioRxiv. 2023 Oct 6.|bioRxiv. 2023 Sep 8.|bioRxiv. 2024 Apr 18:2023.08.31.555808.|bioRxiv. 2024 August 09.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2024 Dec 5:2024.11.29.625709.|bioRxiv. 2024 November 03.|bioRxiv. 2024 November 28.|bioRxiv. 2024 October 26.|bioRxiv. 2024 September 04.|bioRxiv. 2024 September 19.|bioRxiv. 2024 September 23.|bioRxiv. 2025 April 07.|bioRxiv. 2025 Aug 25:2025.08.21.671520.|bioRxiv. 2025 Jan 24:2025.01.22.634215.|bioRxiv. 2025 Jun 7:2025.06.04.657911.|bioRxiv. 2025 May 16.|bioRxiv. 2025 Nov 20:2025.11.20.689490.|bioRxiv. 2025 Oct 25.|bioRxiv. 2025 Sep 21.|Blood Cancer J. 2024 Aug 19;14 (1) :138.|Br J Cancer. 2023 Aug;129 (2) :249-265.|Cancer Biol Ther. 2019;20 (5) :653-665.|Cancer Cell. 2021 Aug 9;39 (8) :1135-1149.e8.|Cancer Cell. 2021 May 10;39 (5) :678-693.e11.|Cancer Cell. 2023 Dec 11;41 (12) :2083-2099.e9.|Cancer Cell. 2024 Jul 8;42 (7) :1286-1300.e8.|Cancer Commun (Lond) . 2025 Jun 10.|Cancer Discov. 2012 Oct;2 (10) :934-47.|Cancer Discov. 2015 Sep;5 (9) :960-71.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2020 Aug;10 (8) :1226-1239.|Cancer Discov. 2020 Jun;10 (6) :872-887.|Cancer Immunol Res. 2021 Feb;9 (2) :136-146.|Cancer Lett. 2017 Nov 1:408:43-54.|Cancer Lett. 2024 Jun 5:217007.|Cancer Res. 2022 Jul 18;82 (14) :2552-2564.|Cancer Res. 2024 Nov 4;84 (21) :3629-3639.|Cancer Res. 2025 Apr 15;85 (8) :1368-1389.|Cancers (Basel) . 2021 Feb 2;13 (3) :581.|Cancers (Basel) . 2022 Mar 11;14 (6) :1451.|Cancers (Basel) . 2023 Apr 13;15 (8) :2280.|Cancers (Basel) . 2024 Aug 7;16 (16) :2785.|Carcinogenesis. 2025 Aug 21:bgaf048.|Cell Biol Int. 2025 Jan;49 (1) :55-67.|Cell Chem Biol. 2018 Aug 16;25 (8) :996-1005.e4.|Cell Death Differ. 2020 May;27 (5) :1520-1538. |Cell Death Dis. 2022 Oct 3;13 (10) :844.|Cell Death Dis. 2024 Nov 13;15 (11) :821.|Cell Death Dis. 2025 Jul 1;16 (1) :482.|Cell Death Dis. 2025 Oct 6;16 (1) :682.|Cell Death Discov. 2023 Sep 19;9 (1) :347.|Cell Genom. 2025 Jul 9;5 (7) :100881.|Cell Metab. 2019 Jan 8;29 (1) :141-155.e9. |Cell Metab. 2025 May 6;37 (5) :1171-1188.e9.|Cell Mol Life Sci. 2023 Mar 18;80 (4) :100.|Cell Oncol (Dordr) . 2022 Dec;45 (6) :1401-1419.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2025 Sep 1;44 (9) :116139.|Cell Rep. 2019 Jul 2;28 (1) :119-131.e4. |Cell Signal. 2024 Sep 16:111415.|Cell Syst. 2019 Jul 24;9 (1) :35-48.e5. |Cell Syst. 2020 Jan 22;10 (1) :66-81.e11.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Cell. 2024 Feb 1;187 (3) :624-641.e23.|Cell. 2024 Jan 4;187 (1) :166-183.e25.|Cell. 2018 Aug 9;174 (4) :843-855.e19.|Cells. 2022 Aug 4;11 (15) :2402.|Chem Biol Interact. 2025 Oct 22:420:111712.|Clin Cancer Res. 2014 Nov 1;20 (21) :5483-95. |Clin Cancer Res. 2022 Sep 1;28 (17) :3836-3849.|Clin Cancer Res. 2023 Apr 3;29 (7) :1232-1242.|Commun Biol. 2025 Apr 24;8 (1) :656.|Comput Struct Biotechnol J. 2019 Feb 8:17:352-361.|Cornell University. 2025.|Dis Model Mech. 2023 Mar 1;16 (3) :dmm049769.|Discov Oncol. 2025 Nov 19;16 (1) :2129.|EBioMedicine. 2020 Jan;51:102583.|EBioMedicine. 2023 Jan:87:104397.|EMBO Mol Med. 2025 Dec;17 (12) :3377-3406.|EMBO Rep. 2025 Jun 17.|Endocrinology. 2024 Sep 26;165 (11) :bqae123.|Eur J Cancer. 2018 Aug:99:37-48.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Mol Med. 2023 Oct;55 (10) :2177-2189.|FEBS Lett. 2024 Dec;598 (24) :3053-3070.|Front Cell Dev Biol. 2018 Sep 25:6:111.|Front Oncol. 2021 Jul 13:11:704042.|Genes Dis. 2021 Jul 1;9 (6) :1650-1661.|Geroscience. 2024 Apr;46 (2) :1861-1879.|Harvard Medical School LINCS LIBRARY|Inflammation. 2023 Aug;46 (4) :1445-1457.|Int Immunopharmacol. 2025 Apr 16:155:114626.|Int J Cancer. 2019 Mar 15;144 (6) :1379-1390.|Int J Mol Sci. 2022 Nov 19;23 (22) :14385.|Int J Mol Sci. 2022 Oct 20;23 (20) :12587.|Int J Mol Sci. 2022 Oct 8;23 (19) :11939.|Int J Mol Sci. 2023 Mar 13;24 (6) :5452.|Int J Mol Sci. 2025 Jun 19;26 (12) :5873.|iScience. 2025 Aug 6;28 (9) :113310.|J Cardiothorac Surg. 2021 May 10;16 (1) :127.|J Cell Biochem. 2016 Jun;117 (6) :1340-51. |J Cell Sci. 2019 May 31;132 (11) :jcs224071.|J Clin Invest. 2023 Jan 17;133 (2) :e153470.|J Clin Toxicol 2014, 4:5|J Clin Toxicol. 2014 October 4, 4:5.|J Exp Clin Cancer Res. 2018 Sep 5;37 (1) :218.|J Exp Clin Cancer Res. 2023 Apr 19;42 (1) :92.|J Exp Clin Cancer Res. 2024 Jun 18;43 (1) :171.|J Exp Med. 2024 Mar 4;221 (3) :e20232028.|J Hepatol. 2021 Aug;75 (2) :363-376.|J Invest Dermatol. 2022 Mar;142 (3 Pt A) :613-623.e7.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|J Med Virol. 2025 Mar;97 (3) :e70267.|J Transl Med. 2022 Jun 7;20 (1) :263.|J Transl Med. 2023 Jan 9;21 (1) :9.|J Transl Med. 2024 May 13;22 (1) :450.|J Transl Med. 2025 Jun 17;23 (1) :660.|J Vasc Res. 2023 Feb 2.|JCI Insight. 2024 Nov 22;9 (22) :e179729.|JCO Precis Oncol. 2024 Apr:8:e2300538.|Johns Hopkins University. 2025.|Leuk Lymphoma. 2021 Feb;62 (2) :337-347.|mBio. 2024 Feb 14;15 (2) :e0319723.|medRxiv. 2023 Nov 13.|Mil Med Res. 2023 Dec 20;10 (1) :68.|Mol Cancer Ther. 2016 Aug;15 (8) :1859-69. |Mol Cancer Ther. 2025 Nov 20.|Mol Cancer. 2023 May 20;22 (1) :86.|Mol Cancer. 2024 Sep 20;23 (1) :204.|Mol Carcinog. 2024 Apr 17|Mol Carcinog. 2025 Jul;64 (7) :1247-1263.|Mol Pharmacol. 2019 Dec;96 (6) :862-870.|Mol Psychiatry. 2022 Nov;27 (11) :4770-4780.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Mol Ther Nucleic Acids. 2024 Jul 19;35 (3) :102283.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Cancer. 2025 Jul;6 (7) :1263-1282.|Nat Cell Biol. 2023 Jan;25 (1) :159-169.|Nat Commun. 2020 Aug 13;11 (1) :4053.|Nat Commun. 2020 May 11;11 (1) :2333.|Nat Commun. 2020 Oct 29;11 (1) :5463.|Nat Commun. 2021 Aug 25;12 (1) :5058.|Nat Commun. 2023 May 19;14 (1) :2859.|Nat Commun. 2024 Mar 21;15 (1) :2551.|Nat Commun. 2024 May 7;15 (1) :3805.|Nat Commun. 2025 Apr 30;16 (1) :4060.|Nat Commun. 2025 Jul 8;16 (1) :6270.|Nat Commun. 2025 Nov 11;16 (1) :9913.|Nat Commun. 2019 Jan 17;10 (1) :296.|Nature. 2025 Jun;642 (8066) :201-211.|Neuro Oncol. 2019 Mar 18;21 (4) :486-497. |Neuro Oncol. 2025 Mar 14:noaf068.|NPJ Precis Oncol. 2025 May 27;9 (1) :156.|Oncogene. 2024 May 17.|Oncogenesis. 2019 Nov 4;8 (11) :65. |Oncol Lett. 2017 Dec;14 (6) :6863-6868.|Oncol Lett. 2022 Feb;23 (2) :51.|Oncol Rep. 2018 Dec; 40 (6) : 3313–3322.|Oncotarget. 2015 Oct 13;6 (31) :31313-22. |Oncotarget. 2017 Feb 28;8 (9) :14835-14846. |Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20180161326A1.|Patent. US20180169102A1.|Patent. US20180291421A1.|Patent. US20200276189A1.|Patent. US20200291111A1.|Patent. US20200308623A1.|Patent. US20200354680A1.|Patent. US20210008047A1.|Patent. US20210010089A1.|Patent. US20220265657A1.|Patent. US20220372134A1.|Patent. US20230049752A1.|Patent. US20230068698A1.|Patent. US20230158019A1.|Patent. US20240140945A1.|Patent. US20240239801A1.|Patent. US20240366605A1|Patent. US20240366605A1.|Patent. WO2019056023A2.|Pharmacol Res. 2025 Dec:222:108027.|Phytomedicine. 2024 Apr:126:155208.|Phytomedicine. 2025 Jan 29:139:156437.|Phytomedicine. 2025 Oct:146:157151.|PLoS Biol. 2020 Jul 17;18 (7) :e3000778.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Preprints. 2024 Jul 8.|Preprints. 2025 Apr 08.|Preprints. 2025 Nov 18.|Proc Natl Acad Sci U S A. 2018 Oct 9;115 (41) :E9570-E9579. |Proc Natl Acad Sci U S A. 2019 Mar 5;116 (10) :4508-4517.|Res Sq. 2025 Apr 14.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 Jul 10.|Research Square Preprint. 2023 May 16.|Research Square Preprint. 2024 Nov 03.|Research Square Preprint. 2024 Nov 06.|Research Square Preprint. 2024 Nov 26.|Research Square Preprint. 2024 Oct 10.|Research Square Print. October 10th, 2022.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2016 Oct 19;6:35531.|Sci Rep. 2017 Mar 28;7:45332.|Sci Rep. 2022 Nov 5;12 (1) :18811.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Sci Signal. 2025 Sep 2;18 (902) :eadw3231.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|SSRN. 2023 Aug 9.|SSRN. 2025 May 30.|SSRN. 2025 Nov 14.|Stem Cell Reports. 2016 Jan 12;6 (1) :74-84.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Technical University of Munich. 2024.|Theranostics. 2022 Oct 3;12 (16) :7051-7066.|Theranostics. 2020 Feb 18;10 (8) :3579-3593. |Toxicology. 2024 May:504:153807.|Transpl Immunol. 2025 Jan 30:102183.|University of California. 2023 Feb.|University of Düsseldorf. 2024.|University of Otago. 2025 Oct 7.|University of Puerto Rico. 2024 Jun.|Vet J. 2024 Dec.|Viruses. 2021 Sep 3;13 (9) :1758.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
041184-AP 200 µL
RPH3A, CT (RPH3A, KIAA0985, Rabphilin-3A, Exophilin-1) (AP) discontinued
Ask
View Details 
041950-Biotin 200 µL
SLC45A3, ID (SLC45A3, PCANAP6, PRST, Solute carrier family 45 member 3, Prostate cancer-associated protein 6, Prostein) (Biotin) discontinued
Ask
View Details